Pharmaceutical Hot Melt Extrusion Manufacturers Technological Advancements

Top Companies in Pharmaceutical Hot Melt Extrusion Market & Their Offerings

Centralize your Pharmaceutical Hot Melt Extrusion Market intelligence and stay ahead - Access the dashboard.

What are the Recent Developments in the Pharmaceutical Hot Melt Extrusion Market?

• In July 2025, Coperion launched its C-BEYOND digital platform to support real-time monitoring of ZSK extruders, helping manufacturers track machine performance, energy consumption, and emissions. The platform is designed to improve production planning, reduce downtime, and strengthen predictive maintenance and process optimization.
• In January 2025, Useon entered into a strategic partnership with the National Fund for Innovation to accelerate machinery development and expand its production capabilities. The investment, supported through the issuance of new shares, is expected to enhance the company’s advanced extruder and pelletizer manufacturing capacity, marking an important step toward long-term innovation and industrial growth.

Supply Chain Analysis

R&D

• R&D in the pharmaceutical hot melt extrusion market is primarily focused on improving the solubility and bioavailability of poorly water-soluble drugs, particularly BCS Class II and IV molecules, through the development of solid dispersions. Ongoing research also emphasizes formulation optimization and advanced drug delivery solutions.
• Key players: Pfizer, AbbVie, Lonza, Evonik Industries, and BASF.

Clinical Trials

• Clinical trials in the pharmaceutical hot melt extrusion (HME) market mainly focus on proving better drug solubility, improved bioavailability, and consistent controlled release, especially for poorly soluble drugs, oral solid dosage forms, and long-acting implants. These studies also evaluate pharmacokinetic performance, bioequivalence with existing therapies, and long-term stability of amorphous solid dispersions.
• Key players: Thermo Fisher Scientific, Coperion, Leistritz, GEA Group, and Lonza.

Formulation and Final Dosage Preparation

• Pharmaceutical hot melt extrusion (HME) formulation involves combining the active drug ingredient with suitable polymers, plasticizers, and surfactants to improve solubility and bioavailability. The blend is processed at controlled temperatures to form a uniform amorphous dispersion, which is then converted into tablets, capsules, pellets, or films.
• Key players: BASF, Evonik Industries, Ashland, Thermo Fisher Scientific, and Catalent.

Market Trends

The global pharmaceutical hot melt extrusion market size was estimated at USD 38.9 billion in 2025 and is predicted to increase from USD 40.76 billion in 2026 to approximately USD 62.11 billion by 2035, expanding at a CAGR of 4.79% from 2026 to 2035. The market is expanding as manufacturers use HME to improve drug solubility, bioavailability, and controlled-release performance. Growth is driven by demand for advanced formulations and continuous, solvent-free production, despite high equipment costs and technical challenges.